Hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and process for their preparation

Abstract

The invention relates to new hydroxyindoles of the Formula, their use as inhibitors of phosphodiesterase 4 and processes for their preparation.

We claim:  
     
       1. A compound of the formula (I)                    
       wherein 
       R 1  is a straight or branched C 1-3  C 1-12  alkyl optionally substituted with a phenyl radical, or  
       C 3-8  cycloalkyl residue radical wherein the phenyl residue radical is optionally substituted with a halo, nitro, hydroxy, C 1-4  alkyl, C 1-4  alkoxy, or COOH residue radical;  
       R 2  and R 3  are each independently of each other hydrogen, or an —OH residue radical where at least one of R 2  and R 3  are —OH;  
       R 5  is a pyridyl residue  radical  disubstituted with a halogen residue radical; and  
       A is a bond, C≡O, or a CHOH residue radical, or the pharmaceutically acceptable salt thereof.  
     
     
       2. The compound of  claim 1 , wherein the compound is a pharmaceutically acceptable salt of an organic or inorganic acid, or of an organic or inorganic base, or a quaternary ammonium salt from the quaternization of a tertiary amine. 
     
     
       3. The compound of  claim 1 , having an asymetric carbon atom by being the L or the D form, or a D,L mixture, and when in a diastereoisomeric form. 
     
     
       4. A compound of  claim 1 , being one of the following compounds: 
       N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide;  
       N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide Na salt;  
       N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-hydroxyacetamide;  
       N-(pyridin-4-yl)-2-[1-2,6-difluorobenzyl)-5-hydroxyindol-3-yl]-2-oxyacetamide;  
       N-(3,5-dichloropyridin-4-yl)-2-[1-(2,6-difluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide;  
       N-(3,5-dichloropyridin-4-yl)-2-[1-(3-nitrobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide Na salt;  
       N-(3,5-dichloropyridin-4-yl)-2-(1-propyl-5-hydroxyindol-3-yl)-2-oxyacetamide;  
       N-(3,5-dichloropyridin-4-yl)-2-(1-isopropyl-5-hydroxyindol-3-yl)-2-oxoacetamide;  
       N-(3,5-dichloropyridin-4-yl)-2-(1-cyclopentylmethyl-5-hydroxyindol-3-yl)-2-oxoacetamide;  
       N-(2,6-dichlorophenyl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl]-2-oxoacetamide;  
       N-(2,6-dichloro-4-trifluoromethylphenyl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2-oxoacetamide;  
       N-(2,6-dichloro-4-trifluoromethoxylphenyl)-2-[1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2-oxoacetamide;  
       N-(3,5-dichloropyridin-4-yl)-2-[1-(4-fluorobenzyl)-6-hydroxyindol-3-yl]-2-oxoacetamide;  
       N-(3,5-dichloropyridin-4-yl)-5-hydroxy-1-(4-methoxybenzyl)indole-3-carboxamide.  
     
     
       5. A process for inhibiting TNFα by administering to a patient in need therefor an effective amount of the compound of  claim 1 . 
     
     
       6. A process for inhibiting TNFα by administering to a patient in need therefor an effective amount of the compound of claim  4   2 . 
     
     
       7. A process for inhibiting phosphodiesterase 4 by administering to a patient in need therefor an effective amount of the compound of  claim 1 . 
     
     
       8. A process for inhibiting phosphodiesterase 4 by administering to a patient in need therefor an effective amount of the compound of claim  4   2 . 
     
     
       9. A process for treating an eosinophil-related condition by administering to a patient in need therefor an effective amount of the compound of  claim 1 . 
     
     
       10. A process for treating an eosinophil-related condition by administering to a patient in need therefor an effective amount of the compound of claim  4   2 . 
     
     
       11. A process for treating a chronic obstructive pulmonary disease, which comprises administering to a patient in need therefor an effective amount of a compound of  claim 1 . 
     
     
       12. A process for treating a chronic obstructive pulmonary disease, which comprises administering to a patient in need therefor an effective amount of a compound of claim  4   2 . 
     
     
       13. A pharmaceutical preparation which comprises a therapeutically effective amount of the compound of  claim 1 , together with one or more of a pharmaceutically acceptable carrier, diluent, and auxiliary ingredient. 
     
     
       14. A process for preparing the pharmaceutical preparation of  claim 7 , which comprises preparing a pharmaceutically acceptable dosage form from a compound of formula (I)and from one or more of a pharmaceutically acceptable carrier, diluent, and auxiliary ingredient.